The Social Community forBiohackers Connect

I do think the having too much data take is interesting. Hypochondriacs are right some of the time, but the rest of the time they could be doing themselves a real disservice.

did AI write this? 😉

Demand for knockoff versions of retatrutide, a peptide-based drug being developed by Eli Lilly, has skyrocketed lately, propelling a gray market that likely exceeds $100 million in annual sales, according to an estimate prepared by The Information that examined many of the market’s biggest suppliers. Retatrutide, or reta as it is commonly called, has become popular among the tech elite, who had already shown great interest in other peptide-based drugs. Reta is potentially far more potent, producing greater weight loss and possibly less muscle loss, but it hasn’t yet won approval from the FDA.

Full Circle

The timing for an IPO seems right—health-based wearables are a thing nowadays. Shares of its closest public competitor, Garmin, are up 18.6% so far this year.